Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Gimeracil/oteracil/tegafur/nivolumab/oxaliplatin

Pruritus and lack of efficacy: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kubota Y, et al. Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience. Cancer Management and Research 14 : 3083-3094, Jan 2022. Available from: URL: http://doi.org/10.2147/CMAR.S351791 Kubota Y, et al. Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience. Cancer Management and Research 14 : 3083-3094, Jan 2022. Available from: URL: http://​doi.​org/​10.​2147/​CMAR.​S351791
Metadaten
Titel
Gimeracil/oteracil/tegafur/nivolumab/oxaliplatin
Pruritus and lack of efficacy: 2 case reports
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30793-3

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Pegaspargase